# Medicine:Generalizing the local average treatment effect

The local average treatment effect (LATE), also known as the complier average causal effect (CACE), refers to the treatment effect among compliers. The LATE may not be of the same value as the average treatment effect (ATE), so extrapolating the LATE directly should be done cautiously. In addition, the LATE retrieved from an experiment may not immediately be externally valid, especially when there is a case for treatment effect heterogeneity (i.e. the treatment effect varies across individuals).  However, generalizing the LATE through reweighting can be attempted, given certain key assumptions.

## Generalizing LATE

The primary goal of running an experiment is to obtain causal leverage, and it does so by randomly assigning subjects to experimental conditions, which sets it apart from observational studies. In an experiment with perfect compliance, the average treatment effect can be obtained easily. However, many experiments are likely to experience either one-sided or two-sided non-compliance. In the presence of non-compliance, the ATE can no longer be recovered. Instead, what is recovered is the average treatment effect for a certain subpopulation known as the compliers, which is the LATE.

When there may exist heterogeneous treatment effects across groups, the LATE is unlikely to be equivalent to the ATE. In one example, Angrist (1989)[1] attempts to estimate the causal effect of serving in the military on earnings, using the draft lottery as an instrument. The compliers are those who were induced by the draft lottery to serve in the military. If the research interest is on how to compensate those involuntarily taxed by the draft, LATE would be useful, since the research targets compliers. However, if researchers are concerned about a more universal draft for future interpretation, then the ATE would be more important (Imbens 2009).[2]

Generalizing from the LATE to the ATE thus becomes an important issue when the research interest lies with the causal treatment effect on a broader population, not just the compliers. In these cases, the LATE may not be the parameter of interest, and researchers have questioned its utility.[3][4] Other researchers, however, have countered this criticism by proposing new methods to generalize from the LATE to the ATE.[5][6][7] Most of these involve some form of reweighting from the LATE, under certain key assumptions that allow for extrapolation from the compliers.

## Reweighting

The intuition behind reweighting comes from the notion that given a certain strata, the distribution among the compliers may not reflect the distribution of the broader population. Thus, to retrieve the ATE, it is necessary to reweight based on the information gleaned from compliers. There are a number of ways that reweighting can be used to try to get at the ATE from the LATE.

### Reweighting by ignorability assumption

By leveraging instrumental variable, Aronow and Carnegie (2013)[5] propose a new reweighting method called Inverse Compliance Score weighting (ICSW), with a similar intuition behind IPW. This method assumes compliance propensity is a pre-treatment covariate and compliers would have the same average treatment effect within their strata. ICSW first estimates the conditional probability of being a complier (Compliance Score) for each subject by Maximum Likelihood estimator given covariates control, then reweights each unit by its inverse of compliance score, so that compliers would have covariate distribution that matches the full population. ICSW is applicable at both one-sided and two-sided noncompliance situation.

Although one's compliance score cannot be directly observed, the probability of compliance can be estimated by observing the compliance condition from the same strata,  in other words those that share the same covariate profile. The compliance score is treated as a latent pretreatment covariate, which is independent of treatment assignment $Z$. For each unit $i$, compliance score is denoted as $P_{Ci}=Pr(D_1\gt D_0|X=x_i)$, where $x_i$is the covariate vector for unit $i$.

In one-sided noncompliance case,  the population consists of only compliers and never-takers. All units assigned to the treatment group that take the treatment will be compliers. Thus, a simple bivariate regression of D on X can predict the probability of compliance.

In two-sided noncompliance case, compliance score is estimated using maximum likelihood estimation.

By assuming probit distribution for compliance and of Bernoulli distribution of D,

where $\hat{\Pr{c_i}}=\hat{\Pr}(D_1\gt D_0|X=x_i)=F(\hat{\theta}_{A,C,x_i})(1-F(\hat{\theta}_{A|A,C,x_i}))^3$ .

and $\theta$ is a vector of covariates to be estimated, $F(.)$ is the cumulative distribution function for a probit model

• ICSW estimator

By the LATE theorem,[2]  average treatment effect for compliers can be estimated with equation:

$\tau_{LATE}=\frac{\sum_{i=1}^n {Z_i}{Y_i}/\sum_{i=1}^n {Z_i}-\sum_{i=1}^n {(1-Z_i)}{Y_i}/\sum_{i=1}^n {(1-Z_i)}}{ \sum_{i=1}^n {Z_i}{D_i}/\sum_{i=1}^n {Z_i}-\sum_{i=1}^n {(1-Z_i)}{D_i}/\sum_{i=1}^n {(1-Z_i)}}$

Define $\hat{w_{Ci}}=1/\hat{Pr_{Ci}}$ the ICSW estimator   is simply  weighted by  :

$\tau_{ATE}=\frac{\sum_{i=1}^n \hat{W_i}{Z_i}{Y_i}/\sum_{i=1}^n \hat{W_i}{Z_i}-\sum_{i=1}^n \hat{W_i}{(1-Z_i)}{Y_i}/\sum_{i=1}^n {\hat{W_i}(1-Z_i)}}{ \sum_{i=1}^n \hat{W_i}{Z_i}{D_i}/\sum_{i=1}^n \hat{W_i}{Z_i}-\sum_{i=1}^n \hat{W_i}{(1-Z_i)}{D_i}/\sum_{i=1}^n \hat{W_i}{(1-Z_i)}}$

This estimator is equivalent to using 2SLS estimator with weight .

• Core assumptions under reweighting

An essential assumption of ICSW relying on  treatment homogeneity within strata, which means the treatment effect should on average be the same for everyone in the strata, not just for the compliers. If this assumption holds, LATE is equal to ATE within some covariate profile. Denote as:

$\text{for all }x \in Supp(X), E[Y_1-Y_0|D_1\gt D_0]$

Notice this is a less restrictive assumption than the traditional ignorability assumption, as this only concerns the covariate sets that are relevant to compliance score, which further leads to heterogeneity, without considering all sets of covariates.

The second assumption is consistency of  $\hat{Pr_{Ci}}$ for $Pr_{Ci}$ and the third assumption is the nonzero compliance for each strata, which is an extension of IV assumption of nonzero compliance over population. This is a reasonable assumption as if compliance score is zero for certain strata, the inverse of it would be infinite.

ICSW estimator is more sensible than that of IV estimator, as it incorporate more covariate information, such that the estimator might have higher variances. This is a general problem for IPW-style estimation. The problem is exaggerated when there is only a small population in certain strata and compliance rate is low.  One way to compromise it to winsorize the estimates, in this paper they set the threshold as =0.275. If compliance score for lower than 0.275, it is replaced by this value. Bootstrap is also recommended in the entire process to reduce uncertainty(Abadie 2002).[8]

### Reweighting under monotonicity assumption

In another approach, one might assume that an underlying utility model links the never-takers, compliers, and always-takers. The ATE can be estimated by reweighting based on an extrapolation of the complier treated and untreated potential outcomes to the never-takers and always-takers. The following method is one that has been proposed by Amanda Kowalski.[7]

First, all subjects are assumed to have a utility function, determined by their individual gains from treatment and costs from treatment. Based on an underlying assumption of monotonicity, the never-takers, compliers, and always-takers can be arranged on the same continuum based on their utility function. This assumes that the always-takers have such a high utility from taking the treatment that they will take it even without encouragement. On the other hand, the never-takers have such a low utility function that they will not take the treatment despite encouragement. Thus, the never-takers can be aligned with the compliers with the lowest utilities, and the always-takers with the compliers with the highest utility functions.

In an experimental population, several aspects can be observed: the treated potential outcomes of the always-takers (those who are treated in the control group); the untreated potential outcomes of the never-takers (those who remain untreated in the treatment group); the treated potential outcomes of the always-takers and compliers (those who are treated in the treatment group); and the untreated potential outcomes of the compliers and never-takers (those who are untreated in the control group). However, the treated and untreated potential outcomes of the compliers should be extracted from the latter two observations. To do so, the LATE must be extracted from the treated population.

Assuming no defiers, it can be assumed that the treated group in the treatment condition consists of both always-takers and compliers. From the observations of the treated outcomes in the control group, the average treated outcome for always-takers can be extracted, as well as their share of the overall population. As such, the weighted average can be undone and the treated potential outcome for the compliers can be obtained; then, the LATE is subtracted to get the untreated potential outcomes for the compliers. This move will then allow extrapolation from the compliers to obtain the ATE.

Returning to the weak monotonicity assumption, which assumes that the utility function always runs in one direction, the utility of a marginal complier would be similar to the utility of a never-taker on one end, and that of an always-taker on the other end. The always-takers will have the same untreated potential outcomes as the compliers, which is its maximum untreated potential outcome. Again, this is based on the underlying utility model linking the subgroups, which assumes that the utility function of an always-taker would not be lower than the utility function of a complier. The same logic would apply to the never-takers, who are assumed to have a utility function that will always be lower than that of a complier.

Given this, extrapolation is possible by projecting the untreated potential outcomes of the compliers to the always-takers, and the treated potential outcomes of the compliers to the never-takers. In other words, if it is assumed that the untreated compliers are informative about always-takers, and the treated compliers are informative about never-takers, then comparison is now possible among the treated always-takers to their “as-if” untreated always-takers, and the untreated never-takers can be compared to their “as-if” treated counterparts. This will then allow the calculation of the overall treatment effect. Extrapolation under the weak monotonicity assumption will provide a bound, rather than a point-estimate.

## Limitations

The estimation of the extrapolation to ATE from the LATE requires certain key assumptions, which may vary from one approach to another. While some may assume homogeneity within covariates, and thus extrapolate based on strata,[5] others may instead assume monotonicity.[7]  All will assume the absence of defiers within the experimental population. Some of these assumptions may be weaker than others—for example, the monotonicity assumption is weaker than the ignorability assumption. However, there are other trade-offs to consider, such as whether the estimates produced are point-estimates, or bounds. Ultimately, the literature on generalizing the LATE relies entirely on key assumptions. It is not a design-based approach per se, and the field of experiments is not usually in the habit of comparing groups unless they are randomly assigned. Even in case when assumptions are difficult to verify, researcher can incorporate through the foundation of experiment design. For example, in a typical field experiment where instrument is  “encouragement to treatment”, treatment heterogeneity could be detected by varying intensity of encouragement. If the compliance rate remains stable under different intensity, if could be a signal of homogeneity across groups. Thus, it is important to be a smart consumer of this line of literature, and examine whether the key assumptions are going to be valid in each experimental case.